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Abstract  
Parasitic diseases have a great impact in human and animal health. The gold 
standard for the diagnosis of the majority of parasitic infections is still conventional 
microscopy, which presents important limitations in terms of sensitivity and specificity 
and commonly requires highly trained technicians. More accurate molecular-based 
diagnostic tools are needed for the implementation of early detection, effective 
treatments and massive screenings with high-throughput capacities. In this respect, 
sensitive and affordable devices could greatly impact on sustainable control 
programmes which exist against parasitic diseases, especially in low income settings. 
Proteomics and nanotechnology approaches are valuable tools for sensing 
pathogens and host alteration signatures within microfluidic detection platforms. These 
new devices might provide novel solutions to fight parasitic diseases. Newly described 
specific parasite derived products with immune-modulatory properties have been 
postulated as the best candidates for the early and accurate detection of parasitic 
infections as well as for the blockage of parasite development. 
This review provides the most recent methodological and technological 
advances with great potential for bio-sensing parasites in their hosts, showing the 
newest opportunities offered by modern “-omics” and platforms for parasite detection 
and control. 
Keywords: detection platforms; diagnosis; proteomics; parasitic diseases; sensors; 
microfluidics.
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1. Introduction 
Parasitic diseases represent particular challenges for human and animal health 
mainly in developing countries. They are strongly associated with poverty causing a 
considerable health and economic impact, especially when considering co-introduced 
and co-invading parasites [1, 2]. Moreover, parasitic infections can be found worldwide 
and can be potentially introduced from endemic to non-endemic areas mainly due to 
human and animal population movements and climate change, resulting in their 
emergence and re-emergence [3, 4]. Neglected parasitic infections are very prevalent 
especially among children and immunocompromised hosts -even in developed 
countries-, causing high morbidity and mortality rates [5, 6]. The lack of appropriate 
diagnostic tools for many of these neglected diseases, combined with their lack of 
appropriate sensitivity and/or specificity, makes the investigation on new type of 
detection devices a must. 
Zoonotic parasites are also the cause of substantive economic losses in livestock 
populations [2]. In this sense, the interest in understanding disease transmission among 
wild and domestic animals, and between them and human population has grown, 
resulting in the emergence of the “one health approach”, which aims to model the 
transmission of parasitic diseases [7, 8]. Detection and transmission control constitute 
significant components to the overall management of many pathogen infections 
(including parasites). Moreover, the rapid diagnosis of many complex parasitic diseases 
with on time treatments and tailored control measurements is essential to avoid 
sequelae, comorbidity and economic losses.
Drug treatment remains as the principal approach for the control of parasites in 
animals; however, parasites have shown molecular resistance mechanisms hampering 
this strategy. Successful and sustainable control strategies depend on the development 
of new tools for targeting both parasites/hosts and vectors [9]. To this end, applying 
new knowledge and techniques in combination with updated mass drug administration 
programmes is essential.  
The Diagnosis of the most health impacting parasites is often cumbersome, 
where current diagnostic tests for important zoonotic parasitic diseases can provide 
incorrect results and so lead to unforeseen consequences [10]. Therefore, there is a 
much-need for rapid, simple, sensitive, and affordable diagnostic tests to improve 
disease control and patient management, mainly in poor-resource settings where 
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diseases like malaria or human sleeping sickness are endemic. In these scenarios, many 
people do not have access to laboratory facilities and many barriers technologies, costs 
and expertise lead to the necessity of incorporate point of care (POC) tests which offer 
flexibility, reliability and robustness for both case detection and large population 
screenings [11].
Outside medical or veterinarian laboratories, rapid on-site diagnosis is very 
important in order to prevent and manage outbreaks and to apply appropriate 
prophylaxis, treatment and control programmes [12]. In this sense, biosensor-based 
tools developed for the diagnosis of pathogens is an emerging issue (131 PubMed 
papers from 2010 when searching “biosensor diagnosis pathogens” on December 2015) 
and ultimately a growing area of concern when referring to the diagnosis of parasitic 
infections (38 PubMed papers from 2010 when searching “biosensor diagnosis 
parasites” on December 2015). 
The main goal of this emerging area of knowledge is to develop devices with 
multiplex capabilities as suitable screening methods for the detection of several 
parasites and their corresponding vectors. Despite the recent advances in bio-sensor 
technology for infectious and parasitic diseases, they still remain as one of the major 
causes of mortality and morbidity throughout the world. This review presents current 
examples and perspectives for integrating modern sensing technologies for the detection 
of parasitic diseases.  
2. Predictive candidates to detect parasitic diseases 
Candidate biomarkers for the diagnosis of parasitic diseases must be identified in 
differentially expressed molecules between healthy subjects and infected patients. The 
first step towards an effective treatment of parasitic infections is an early detection and 
later differentiation of the disease progression and/or recurrences over time. Having into 
account the variations of the individual immune responses to the infection, the 
identification of candidate biomarkers is a more appropriate approach for reliable and 
specific parasite identifications than defining a single candidate. Thus, a combination of 
key hosts and parasite molecules is ideal to be included in target panels with the aim of 
achieving low overlapping between different diseases, and therefore, facilitate an 
integrated diagnosis.  
Protein-protein interactions at the host-parasite interplay are highly relevant in 
the context of modifying protein expression levels and inducing protein expression. 
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Identifying these alterations in host protein profiles during infection could facilitate the 
understanding of disease pathogenesis, host immune response, and identification of 
potential protein markers for the detection and prognosis of the disease. In this sense, 
parasitic infections may lead to highly relevant alterations on the level and expression of 
multiple serum proteins involved in essential physiological pathways (i.e. lipid-binding 
proteins) as well as in the change of very specific host molecules (i.e.- the host 
erythrocyte membrane proteins during malaria infection) [13, 14].  
Investigating the metabolic consequences of parasitic infections in the host is 
now feasible based on modern technological advances. Experimental infections with 
single or multiple parasite species may allow the discovery of specific or common 
biomarkers although they should be further validated in free-living populations [15]. To 
this end, for example, it has been shown by serum proteomics of Eimeria sp infected 
chickens that proteins usually not detected in the blood like those associated with 
mitochondrial metabolism are good candidates for time-course studies in coccidiosis. 
However, the host genetic background leading to different levels of susceptibility is a 
key factor in the alteration profile of proteins [16]. 
Regarding parasite-derived molecules, the strategy to detect circulating antigens 
has the potential to discriminate active from past infections. Assessment of antigens 
during a given infection and specifically the excreted-secreted or surface-exposed 
parasite proteins should be the best for an accurate immunodiagnostic procedure. The 
study of the surfome in parasites is revealing novel molecular targets for specific 
diagnosis. Many of these molecules are represented by glycoproteins located at the 
extracellular region attached to the plasma membrane, although antigenic variability at 
this level makes the selection of molecules cumbersome [17, 18]. This highlights the 
importance of comparative surfome analysis to increase the chance to find specific 
targets in parasites, leading to differential surface markers useful to avoid potential 
misdiagnosis like for example of Chagas' disease [17]. In addition, the potential 
detection of fine post-translational modifications creating neo-epitopes during specific 
parasitic disease pathogenesis could lead to monitor disease activity, like in many 
human diseases [19].  
Epitope mapping studies aimed to identify unique diagnostic molecules from 
polymorphic immune-dominant antigens in parasites using computational methods is 
also a promising area [20]. For instance, the identification of many novel epitopes with 
diagnostic potential has been proved for the protozoan Trypanosoma cruzi [21]. 
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Moreover, the detection of new diagnostic epitopes from circulating antigens is also a 
practical diagnostic strategy.
Some of the putative new protein biomarkers to detect parasites are likely to be 
present in biological fluids at extremely low concentrations and protected inside 
secreted microvesicles. Microvesicle-based secretion seems to be a general mechanism 
for protein secretion by protozoan parasites. It is well reported that the biomolecular 
cargo (i.e. proteins, lipids, nucleic acids) inside these microvesicles is involved in 
signalling for parasite infection and its survival therefore it could be also exploited in 
disease treatments [22, 23]. Since extracellular vesicles are highly immunogenic, they 
can be considered as suitable candidates to detect parasitic diseases [23]. 
3. Proteomic platforms for the identification of parasite biomarkers.
Parasites have complex life-cycles and redundancy molecules can be found in 
many infectious processes, posing additional difficulties for their specific identification 
by classical biochemical approaches. Additionally, parasitic infections may alter the 
metabolic activities in their host being these alterations the basis of metabolic 
fingerprint approaches for understanding the metabolic consequences of the infections. 
Therefore, these could be considered as a source for novel diagnostic or prognostic 
biomarkers [15]. Nowadays, modern –omic technologies are offering high-throughput 
strategies for such a difficult system biology exploration, with the essential support of 
novel bioinformatic tools [24, 25].  
The identification of biomarkers of parasitic infections by differential protein 
profiling of specific hosts or parasitic molecules is a promising area; mainly based on 
induced changes by parasites at post-translational modifications, peptide degradations 
or protein variants [26]. Tissues (human and animal) and proximal bio-fluids could 
contain molecular information on the physiological and pathological state of the 
organism since these tissues and bio-fluids are the route and destination of parasites 
and/or their secretions. The proteomic characterisation of proximal bio-fluids may 
provide useful and comprehensive information for diagnostic, prognostic and predictive 
biomarkers. The challenge is the detection of very low abundant protein circulating 
biomarkers -this kind of molecules provides a greater amount of downstream 
information content than nucleic acids- that may be essential for early diagnosis [27]. 
3.1 The Potential of Mass Spectrometry  
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Briefly, Mass Spectrometry (MS) is a robust, versatile and sensitive analytical 
technology allowing high-throughput detection with mass accuracy, precise quantitation 
and verification of protein variants, splice isoforms, metabolites and disease-specific 
post-translational modifications from tissues, body fluids or cell cultures [28, 29]. 
Highly sensitive technologies and high-throughput systems -like MS- are promising 
tools for novel biomarkers since MS allows characterisation of the fine tune changes in 
proteins, -including differences at population level- [30].  
Commonly, MS-based proteomics approaches are a suitable resource to identify 
biomarkers for the detection of parasites as the main technique or coupled with other 
proteomic and conventional biochemical techniques. For instance, this is the basis for 
the identification of potential malaria markers in patient´s sera and recently applied to 
identify specie-specific proteins in infected patients [31, 32]. 
De Bock and colleagues highlighted the potential of MS-based technologies (i.e.
surface-enhanced laser desorption/ionisation time of flight-MS, SELDI-TOF-MS) as 
research tools to interrogate protein-based biomarkers in parasitic diseases. In general, 
SELDI-TOF determines differential specific protein profiles (in particular, low 
molecular weight molecules) in proximal bio-fluids. The above-mentioned technology 
has also been applied in parasitic diseases by sensing unusually truncated host proteins 
in response to Trypanosoma cruzi infection with high sensitivity and specificity [33]. 
Moreover, matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) is a 
valuable diagnostic technique already applied for detecting and differentiating 
Entamoeba Spp or Babesia canis canis infections, and becoming a miniaturised 
bioanalytical tool for detecting and discerning proteins from bio-complex samples [34-
36]. MALDI-MS has applications in biomarker discovery, pathogen identification and 
has great potential for lipid-based biomarker sensing [37, 38]. For the identification of 
vectors like mosquitoes, MALDI-TOF allows accurate identifications which are 
important to elucidate their role as vectors. Importantly, the technique has also the 
potential for rapid in one-shot dual identifications (vectors and pathogens) [39, 40]. The 
utility of MS in routine analyses to point out markers of parasitic infections in bio-fluids 
and tissues was proved to be effective in many recent publications (Table 1), but still 
needs to be broadly used for research and clinical diagnosis. Many pre-analytical 
protocols during parasite sample preparation must focus on maximising the number of 
protein identifications on perform highly-reproducible assays.  
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Other MS-based techniques, not predominately applied in diagnostic 
parasitology, but that hold great potential for the development of this area are:  
(i) MS imaging is an analytical tool providing information on the spatial distribution 
and relative abundance of biomolecules in tissues [37]. Its power depends on an 
unbiased preliminary knowledge of molecular identities required, its ability to 
distinguish between diseases with similar histological characteristics, the different type 
of molecules detected, the quality of tissue preservation/conservation and the unique 
applications for clinical diagnostics [60]. It would probably be advantageous to correlate 
molecules and pathogenesis of impacting diseases like severe malaria, severe 
hepatosplenic schistosomiasis and cutaneous forms of leishmaniasis.  
 (ii) An emerging technology for pathogen detection is PCR–electrospray ionisation 
MS, a versatile technique to characterise multiple strains and organisms having high 
potential to identify tick-borne pathogens [61, 62].
(iii) Multiple reaction monitoring mass spectrometric assays can be used in order to 
quantify multiple protein isoforms, specific proteins or modified peptides [63]. This 
technique requires enriched samples to accurately analyse modified biomolecules like 
lipopolysaccharides, glyco-sphingolipids and glycoproteins, which are highly relevant 
antigens of parasites [64]. 
(iv) Direct identification of compounds originated from pathogens 
physiology/metabolism within hosts can be done by metabolomics approaches [65]. 
Metabolomics profiles based on MS strategies detecting variations in differential 
metabolic signatures in cells, tissues or body fluids, may open a way for sensing 
parasites. When trying to detect and understand host or parasite derived metabolites at 
low concentration, capillary electrophoresis MS with electrospray ionisation and gas-
chromatography MS offer valuable discriminatory power [66-68]. It could be also 
applied to time-course and accumulation of drug metabolites after treatment of parasitic 
diseases. 
3.2 Nanoproteomics
 Nanoproteomics is a new “-omic” emerging discipline coming from the 
advances and integration of nanotechnologies and proteomics, useful for rapid 
diagnostic screening at nanometer scale in the clinical practice. Nanotechnology has the 
potential to minimise most of the problems related to the proteomic technologies (i.e
complexity, protein modifications) providing advantages at the detection level and 
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allowing new methodological approaches such as multiplexing thus opening new 
biologically relevant insights [69].  
 Multiplexing is an important feature that may facilitate the simultaneous study of 
different parameters within a unique platform. Protein and glycan microarrays, bead 
arrays or 3D printings are some of the methodologies included in this field within on-
demand diagnostics platforms. The use of dynamic sensing arrays based on micron 
and/or nano-sized beads allows increasing the level of multiplexing with the potential to 
be adaptable in microfluidic devices for immunoassays [70]. Protein microarrays are 
miniaturised immunoassays in an array format which allows the study of thousands of 
proteins simultaneously, offering the opportunity to perform high-throughput screening 
for new biomarkers of infectious and parasitic diseases at the global level [71, 72]. 
Peptide chips could be a good strategy for the identification of potential 
immunodominant antigens and for epitopes description [73]. Biochips immuno-like 
polymer membranes for POC sensing of proteins in serum samples is also an interesting 
field [74]. In fact, novel single-domain antibodies (i.e. scFvs, nanobodies), may offer 
interesting advantages over monoclonal antibodies if applied to these methodologies 
[75, 76]. 
 Glycan microarrays are also powerful tools for biomarker discovery. These 
microarrays have the potential to identify carbohydrate antigens and improve the 
serodiagnosis of different parasitic infections, although advanced methods for the 
synthesis, isolation, and characterisation of glycans are still required [77-79]. The 
diagnostic potential of glycans found in Leishmania, Schistosoma and Trichinella 
parasites points outs their relevance. 
3.3 Subcellular proteomics 
The analysis of the composition of particular purified cellular compartments is 
gaining importance in diagnostic research. Extracellular vesicles represent a promising 
source of circulating biomarker cargo encapsulated in a lipid coat. Among them, 
exosomes, 40-100 nm in size vesicles, which are important in inter-cellular 
communications, play critical roles in many biological functions. Exosome surface 
protein contents can be a rich source of biomarkers in blood samples and proximal 
fluids. These vesicles could have a high potential as optimal diagnostic targets based on 
the differential display of specific exosomal protein markers. Exosome-MS protein 
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libraries prepared by either the shave -for surface protein exosomal markers- or 
complete exosome material, produce ideal peptide libraries for MS/MS analysis.  
There are accumulating evidences of the release of inter-communicating 
extracellular vesicles in parasitic diseases, being an integral part of the parasite’s 
infectious life cycle [80, 81]. The potential that proteomics, especially MS, shows for 
sensing and deciphering the cargo of these parasite or host secreted biomarker enriched 
microvesicles is very high in the field of parasitic diseases diagnosis [82]. The detection 
of parasitic derived microvesicles would be highly valuable for example to diagnose and 
guide management of chronic and complex asymptomatic diseases, such as cystic 
echinococcosis or in vector transmitted infections like Leishmaniasis, in which 
exosomes are newly identified virulence factors [81].  
Molecules in the exosome cargo like the microRNAs have also great potential 
for the diagnosis of parasitic diseases [83]. Another type of analytes that could be 
studied in the exosome space, e.g. lipids, might represent good biomarkers to 
investigate in the near future. All these provide an important base to continue 
researching in parasite derived exosomes as diagnostic targets and demonstrating their 
utility as clinical biomarkers.  
4. Parasite testing: biosensor based platforms 
There is an important demand in parasitic disease diagnostics for portable and 
highly sensitive systems. Novel detection platforms have the potential to develop 
robust, multiplexed ultrasensitive protein detection devices with high efficiency, high 
data quality, and cost-effectiveness for the identification of pathogens and disease 
biomarkers in both well-equipped and/or limited clinical facilities [84].  
Biosensors are also new molecular technologies that attempt to overcome many 
of the detection limits due to the low abundance of key biomarkers [85]. Some of these 
technologies have impressively improved sensitivity compared to conventional 
immunoassay approaches [86]. However, few biosensors have been developed and 
commercialised for the detection of infectious or no infectious diseases, but none of 
them for parasitic diseases.  
Biosensors can be used as POC devices to detect host and parasite virulence and 
specific biomarkers, being good alternatives to current standard methods [87]. These 
biomarkers can be transferred to a biosensor format for multiplexed ultrasensitive 
sensing directly from proximal body fluids, enabling simultaneous detection of specific, 
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to several evolutive forms, antibodies. This biomarker serves as revolutionary POC 
diagnostic technology to improve the prevention, control, and treatment of parasitic 
diseases. The inclusion of species-specific markers for differential diagnosis and 
polymorphism detections would directly impact sensing and help to understand 
parasites. The integration of high-throughput -omic data, which is relevant to essential 
host-parasite interaction networks, within these biomarkers appears as the most accurate 
scenario to understand and guarantee infection status. 
These devices have the potential to identify single molecules without the use of 
microscopes and moreover the same device could potentially be used for several 
different tests for biomarkers and bio-particles, providing an interesting alternative to 
standard tests like PCR [87]. This could be very advantageous in low-resource settings 
where people may not be well trained even in standard test and few technologies are 
well-established at a POC level, or where the conditions are not appropriated for 
analysis.  These devices will be particularly useful to detect invasive infections or to 
prevent further disease spread in populations that still rely in conventional 
parasitological techniques. 
Advanced developments for onsite diagnosis could come from single cell 
proteomic studies with a microfluidic antibody capture chip platform, able to detect 
target markers in real clinical practice [88]. However, the impact of microfluidics on 
interesting markers like for example exosomes is still small. Therefore, interfacing 
biosensors with MS is leading to the high-resolution identification of macromolecules 
and thus, search for parasitic targets [89]. The interrogation of protein biomarkers in 
specific cell types and during defined periods in hosts constitutes a potential emerging 
area of research to provide key advances in the field of parasitology. This could be 
especially relevant for understanding (i) anti-parasite immune responses in different 
clinical forms of parasitic diseases (i.e. Chagas disease) and their role driving the 
development of this disease and (ii) the systemic impact of parasitic infections. 
The development of specific methodologies is still required to accomplish and 
integrate all the above technologies in a high quality and robust sensing device. The 
ultimate advances in bio-fabrication techniques allow creating biosensors with living 
cells in 3D to more closely model the in vivo cell environment, having these devices the 
potential to combine bio-sensing and therapeutic treatments [90]. The implementation 
of these tests on clinical applications might positively influence animal and human 
clinical management as well as significantly reduce costs. 
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4.1 The potential of biosensors to detect and diagnose parasites 
The diagnosis of many parasitic diseases relies on showing parasites in tissue 
samples and on standard tests, nevertheless there are still gaps in the diagnosis of well 
know parasites or even in distinguishing between species and subspecies [91] (Table 2). 
The lack of diagnostic tests influences decisively health care decisions. In general, 
parasitological techniques oriented to detection by microscopic examination have many 
disadvantages such as: they are mainly invasive, leads to misdiagnosis, require expert 
microscopists, they are time consuming and lacking of accuracy [112]. Moreover, many 
rapid diagnostic tests lack accuracy, validation, or both. At the hospital level, but even 
more in the field, there is an increasing demand for better diagnostic tests to detect 
parasitic diseases at an early stage.  
The pathogenicity and life cycles of parasites are highly complex and governed 
by the parasite–host interactions. The trend is, instead of testing for a single biomarker, 
to identify the panel of biomarkers that together may be better predictors of clinically 
relevant parasites towards efficient decision-making in individual POC settings. As 
commented previously, MS and proteomic techniques can assist as standard tools for 
the identification of infection induced up and down regulations that may serve as 
specific protein biomarkers. Moreover, host-derived metabolic and specific 
pathogenicity sensors would also play a role modulating parasitic disease progression to 
ensure survival and long-term persistence [113, 114].  
In this sense, the infection and persistence by protozoan parasites is associated 
with changes in host tissue protein composition, highlighting that both parasite and 
host-derived molecules modulate disease progression [113, 115]. For instance, these 
kind of bidirectional protein signatures have been identified by proteomics in 
Plasmodium falciparum [116]. Also, in the management of the complex 
Echinococcosis, was recently suggested that a combination of markers would be highly 
desirable for the follow-up of threated patients to avoid recurrence [110]. Moreover, an 
integrative approach that looks for an effective diagnosis was also suggested for 
Schistosomiasis [117]. 
4.2 The critical role of biosensors in important parasitic diseases. 
The broad technologies underlying biosensors have experienced many 
developments, with the goal to enable small, sensitive and easy-to-use devices. As 
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mentioned in previous points, micro- and nanotechnologies can offer new technological 
tools and potential applications for developing bio-sensing devices for infection´s 
biomarkers. Many of these biosensors have proven to be useful for the detection of 
pathogen signatures and circulating proteins in patients [118]. The access to timely and 
accurate diagnostic tests has a significant impact in the management of many parasitic 
diseases like malaria.   
At present, many microfluidic platforms are under development in order to 
address the main disadvantages presented above. Microfluidics provides an ideal 
interface for the manipulation of cells (i.e. red blood cells) or even the microorganisms 
in a completely integrated system that can be fabricated in mass production at low costs 
(Table 3). These devices have the potential of contributing to the diagnosis, control and 
treatment of malaria. In the near future, by using a drop of blood obtained from a finger 
pick, these assays could be automated to reduce human interventions in sample analysis 
for easy and massive large population screenings. 
Sissel Juul and colleagues developed an impressive device, based on droplet 
microfluidics, in 2012 [137]. The microfluidic device is able to specifically and 
sensitively detect malaria-causing Plasmodium parasites employing isothermal 
conversion of single DNA cleavage-ligation events catalysed specifically by the 
Plasmodium enzyme topoisomerase I and detectable at the single-molecule level. This 
device allows for sensitive, specific, and quantitative detection of all human-malaria-
caused by Plasmodium species in single drops from whole blood with a detection limit 
of less than one parasite/μL.
Very recently Warkiani and colleagues [138] developed a highly integrated 
system that allows enrichment and purification of malaria parasites from whole blood 
using a label-free, shear-modulated inertial microfluidic device. From 2 to 10 parasites 
were separated per millilitre and quantified using qPCR. This technique is 
approximately 100-fold more sensitive than conventional microscopy analysis of thick 
blood smears and ideal for further integration into an automatic system with 
downstream detection for POC diagnostic devices. 
Red blood cells (RBCs) infected with malaria can be easily detected using 
microfluidic devices by looking at the morphological changes on the surface of the 
RBCs. Using controlled surface roughness and shear forces in a microfluidic channel 
malaria infected RBCs can be slowed and eventually immobilised on the roughened 
surface from whole blood. Although not well optimised for being used as POC device, 
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it is ambitioned to be an alternative biomarker for malaria diagnosis [124]. Following 
the same concept of looking at RBCs, Quan Guo and coworkers [128] developed a 
microfluidic technique for measuring the deformability of single RBCs based on their 
ability to deform through micrometre-scale constrictions. Although slow and tedious to 
extract information from the device is able to distinguish among uninfected RBCs and 
RBCs with various stages of P. falciparum infection. 
Other ways of parasite detection are the fabrication of special flow-through 
separator structures inside the microfluidic channel for trapping parasites [139] or the 
apertures designed by Chunxiao Hu and collaborators [140] that form a trap were the 
parasite are trapped around a mid-point of its body. These types of traps have been used 
for differentiating plant parasitic nematodes by their stylet activity trough integrated 
electrodes that record electrical signals.  
An interesting review reported some relevant biosensors developed in POC 
system for an important vector-borne infection as dengue, highlighting their enormous 
potential in this field [141]. In general, technologies based on biosensors have been 
applied in diagnostic investigations of a wide range of parasites as can be seen in Table 
4. In this way, advanced research through the integration of different techniques for 
multiplexing and high-throughput analysis on a chip might lead to the development of 
multi-parasite detection devices highly advantageous for tropical parasitic diseases [161, 
162]. Moreover, microfluidic devices open new avenues to investigate full parasite 
behaviour [163, 164] and parasite drug response [165] in order to design new strategies 
to fight them. These technologies are also applicable in toxicology and drug discovery 
programmes for human metabolic studies and degenerative diseases.  
In particular, rapid developments are occurring in the field of paper based 
analytical devices (µPADs). µPADs are a new type of analytical platforms for 
ASSURED diagnostic tests (Affordable, Sensitive, Specific, User friendly, Rapid and 
robust, Equipment free, Deliverable to end users, World Health Organisation). These 
devices should be simple to use, portable, inexpensive able to detect multiple analytes, 
and usable in using small volumes of sample. Therefore, the perfect tools for parasite 
detection in developing countries are coming. For instance, Horning and co-workers 
[166] developed a paper microfluidic cartridge for the automated staining of malaria 
parasites with acridine orange prior to microscopy. The cartridge enables simultaneous, 
sub-minute generation of both thin and thick smears of acridine orange-stained 
parasites, and has the potential to be used in limited-resources settings (Figure 1).  
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In the tropics and in the resource-limited settings, water-borne parasites are 
among the most important parasitic diseases and many obstacles prevent their detection 
[167]. There is a need for rapid and simple screening of water sources to protect human 
health from water-related diseases. Currently, information about compact imaging 
systems incorporating a chip-scale microscope brings light to the diagnosis of major 
enteric parasites to save many lives [168]. Also, devices can track infectivity as early as 
12 h post-infection, faster than other state of the art techniques [169]. Therefore, efforts 
are needed to facilitate market entry of these new technologies and facilitate 
mechanisms for their implementation. It is believed that PADs represent a realistic 
alternative for low cost, mass production and marketable devices. Moreover, the 
transition of paper-based microfluidic devices from the laboratory into the market need 
to be accomplished by providing the effective fluid flow control on paper and 
developing paper compatible easy and cheap sensing mechanisms.  
Other important parasites are those food-transmitted, which are generally under-
detected. These food-borne parasites have complex life cycles, which made difficult 
their control. In addition, few food-borne parasitic pathogens are effectively monitored 
in food [170]. Actually, there is a tremendous need to track back food-borne infections 
using new technologies such as biosensors due to their high specificity and potential to 
decrease the detection times [171].  
5. Conclusions and Perspectives 
An efficient diagnosis is very important for the prevention and treatment of 
infectious and parasitic diseases. Bio-sensing devices based on a high-throughput 
format could have a favourable impact on disease screening and control 
implementation. New proteomics developments and their adaptation to POC may allow 
in a near future to produce low cost devices, increasing the sensitivity and shortening 
the time of detection compared to conventional tools. 
In this sense, there is an important need to start developing and commercialising 
devices focusing on POC diagnostics applications in human and veterinary parasitology. 
These devices would favour the overall health of people in developing countries by 
taking broad and on time prevention and control measures and by assessing the 
treatment efficacy and facilitating the understanding the distribution patterns of hosts 
and vectors of important zoonotic parasitic diseases. Moreover, key biosensors might 
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allow the on-site molecular characterization of multi-parasite species bringing important 
information on the complex host-parasite interplay. 
The convergence of proteomics and nanotechnology more likely will provide 
specific immune-sensors and immune-assays for detecting biomarkers related to 
infections. In this regards, the development of portable POC diagnostic tools for 
detecting circulating exosomes as biomarkers, therapeutic targets and signalling 
molecules of parasitic origin is a feasible and important goal in parasitology research. 
The integration of data from detected parasitic molecules and changes detected in host 
immune and metabolic responses to the infection might provide detailed sensory 
information for precise molecular-level diagnostics and monitoring tools.  
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Figure legends: 
Figure 1: New type of analytical paper microfluidics for sensing parasites. A) A 3D 
representation of the cartridge. B) A top-down view of the cartridge. C) A cross-section 
of the cartridge, emphasizing the slanted nature of the coverslip during use, which 
permits imaging in both thick (many cells) and thin (single cell) regions. Reproduced 
with permission from [Matthew P. Horning et al 2014] © 2014, The Royal Society of 
Chemistry.
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Table 1. New potential biomarkers identified in host-parasite models found by mass spectrometry techniques. 
Disease/Parasite Biomarkers Source Method Features/Details References
Trypanosoma cruzi
T. rangeli 
T. brucei gambiense 
C3a anaphylatoxin,
apolipoprotein A 
fibronectin 
T. rangeli GP63-related protein and an 
FCaBP protein 
Osteopontin and β-2-microglobulin 
Serum
Serum 
Cerebrospinal fluid  
Mass Spectrometric Profiling
by SELDI-TOF 
MS/MS analysis 
MALDI TOF-TOF MS 
Useful for subjects with latent Chagas 
Disease 
Proteins from trypomastigote surfome 
Good candidates for the development of a 
test for staging patients
[41]
[42] 
[43] 
Schistosoma 
mansoni 
Fuco-oligosaccharides that are 
produced by schistosome eggs 
Phenyl acetyl glycine (PAG) 
Urine MALDI-TOF
UPLC-MS 
Oligosaccharides detected in infection
urine are shown to be excreted by live 
eggs and not by worms 
PAG is a statistically discriminant 
metabolite which can provide important 
information regarding the disease
[44]
[45]
Plasmodium 
falciparum 
P. berghei 
Metabolites between supernatants from 
Plasmodium: 3- methylindole, 
succinylacetone, S-methyl-L-
thiocitrulline, O- arachidonoyl glycidol 
Urinary metabolites: UK1, UK2 
Proteins: cE5, B3VDI9_ANOGA, and 
AGAP008216-PA 
In vitro cultured 
samples  
Urine 
Salivary gland samples 
from Anopheles 
gambiae
High resolution metabolomics 
(HRM): C18 liquid 
chromatography coupled with 
Fourier-Transform Mass 
Spectrometry (FTMS) 
Nuclear magnetic resonance 
(NMR) profiling followed by 
LC-MS 
SELDI-TOF-MS 
Low molecular-weight metabolites for 
future development of non- invasive 
malaria diagnostic tools 
Two unique structurally related urinary 
candidate biomarkers have not been 
described so far in the eukaryotic 
organism. 
Markers involved in blood feeding 
[46]
[47] 
[48] 
Echinococcus spp Antigen B-related molecules (EgAgB; 
EgAgB1-5)
Sera MALDI-TOF-MS Immunodominant epitopes changed as the 
disease progresses
[49]
Giardia lamblia Encystation-specific vesicles (ESVs) 
and  endocytic organelles termed 
peripheral vesicles (PVs)
Microsome fractions 
derived from 
trophozoites
Combining flow cytometry-
based organelle sorting with 
In silico filtration of mass 
Proteins from Secretory and Endocytic 
Organelles: 
[50]
spectrometry data
Entamoeba 
histolytica
Cyst-wall specific glycoproteins Jacob, 
Jessie and chitinase
Fecal specimens LC-MS/MS mass 
spectrometer
Promise as diagnostic targets [51]
Eimeria /Coccidiosis Proteins from the neck region (rhoptry 
neck proteins, RON): RON2L1, 
RON2L2
Serum Gel LC– MS/MS From enriched rhoptry fractions isolated 
from the sporozoite stage 
[52]
Toxoplasma gondii Excretory secretory antigen (ESA): 
microneme protein 10 and dense 
granule protein 7, phosphoglycerate 
mutase 1
Serum MALDI-TOF-TOF From tachyzoites [53]
Trichinella spiralis Excretory-secretory (ES) proteins of 
muscle larvae (ML) 
Serum MALDI-TOF Come mainly from the excretory granules 
of the stichosome and the cuticles 
membrane
[54]
Porcine cysticercosis 
(Taenia solium) 
Clusterin, lecithin-cholesterol 
acyltransfer- ase, vitronectin, 
haptoglobin and apolipoprotein A-I
Serum SELDI-TOF technology Detection of viable cysts (active disease) [55]
Leishmania 
infantum 
Profile of the volatile organic (VOCs) 
emitted 
Proteins Li-isd1, Li-txn1, Li-ntf2 
Hair sample
Urine 
Solid-phase microextraction 
(SPME) combined with gas 
chromatography-mass 
spectrometry (GC-MS) 
RP-HPLC-MS 
Significant variations between healthy 
dogs (G1) and infected dogs (G2+G3). 
To distinguish active visceral 
leishmaniasis from asymptomatic 
infection
[56]
[57]
Trichomonas 
vaginalis 
Papain-like (TvCP2, TvCP4, TvCP4-
like, TvCPT), and one legumain-like 
(TvLEGU-1) cysteine proteinases(CPs) 
Serum MALDI-MS and ESI-LC-
MS/MS 
Antigen cocktail of recombinant 
proteinases that could increase the 
sensitivity and specificity for the 
immunodiagnosis
[58]
Teladorsagia 
circumcincta
(parasitic nematode)
Gelsolin, α-1 b glycoprotein and 
haemopexin 
Lymph formed from the 
interstitial fluid (sheeps) 
MALDI-TOF and MS/MS 
analyses 
The proteomic study of lymph has the
potential to give new insights into local 
responses to infection
[59]
Table 2. Some key problems to diagnose parasitic diseases and encountered in existing diagnostics for a range of important parasitic species. 
PARASITIC DISEASE PROBLEMS RELATED TO THEIR 
DIAGNOSIS
SPECIES DIAGNOSTIC 
METHOD
DEFICIENCIES/INADEQUACIES REFERENCES
MALARIA 
-Conventional microscopy is the gold 
standard for malaria diagnosis. 50-100 
parasites/µl of blood can be detected in a 
good lab. Sensitivity is only 500 
parasites/µl in non-specialized labs. 
Requires expertise. 
-Great difficulty of establishing quality-
assured microscopy in rural and resource-
poor settings.  
-Field implementation of many techniques 
remains a problem.  
- Rapid diagnostic tests have good 
sensitivity for densities of P. falciparum
greater than 500 parasites/μL. However, the 
World Health Organization recommends a 
lower sensitivity limit of detection for rapid 
diagnostic test for P. falciparum of 95% at a 
parasitaemia of 100P/μL.
- Current tests are essentially qualitative 
and do not quantitate the risk of developing 
severe complication. 
- Most RDTs that detect multiple species do 
not differentiate non-P. falciparum species 
from each other, nor do they differentiate 
mixed infections of P. falciparum and non-
P. falciparum from P. falciparum
monoinfection. 
-Placental malaria poses a great diagnostic 
challenge, lack of accurate and sensitive 
diagnostic tool for malaria infections in 
pregnancy.
Plasmodium falciparum Hematological parameters 
(Analytical Biochemistry)
Unreliable laboratory indicators in 
acute uncomplicated malaria
[92]
Nested PCR Time-consuming, open to 
considerable risk of contamination, 
low cost-efficiency and low 
sensitivity and specificity in certain 
cases.
[93]
Light microscopy Their efficacy is affected by several 
key factors such as the level of 
parasitemia, among others.
[94]
Histopathology Frequently not available in most 
settings, relatively costly and labor 
intensive.
[95]
Rapid diagnostic tests The specificities, sensitivities, 
numbers of false positives, numbers 
of false negatives and temperature 
tolerances of these tests vary 
considerably 
Performance varies between lots and 
widely between similar products. 
Also varies the concentration in the 
blood of the protein to be detected. 
[96]
[97] 
LEISHMANIASIS 
-Heterogeneity of Leishmania parasites 
complicates the diagnosis.  
-Proteins stage-specifically expressed and 
associated with virulence have a high 
antigenicity during the active disease phase.
Leishmania 
infantum/donovani 
Quantitative PCR Invasive samples for accurate 
detection
[98]
Serology The specifications for VL diagnostic 
tests vary among the different 
endemic regions. 
[99]
-Antigens used in serology show a large
number of cross reactions with other 
trypanosomatids. 
-Invasive parasitological methods currently 
used to identify infected 
Individuals.
Leishmania braziliensis No gold-standard test for tegumentary 
leishmaniasis, a combination of 
different diagnostic techniques is 
often necessary.
[110]
Serology (ELISA) Potential as an alternative method for 
confirmation.
[101]
TRYPANOSOMIASIS 
-No symptoms in acute or chronic phase
and once the immune response is 
established, parasite detection is very 
difficult. 
-Misdiagnosis between species. 
-There is currently no single reference 
standard test. 
-Methodological limitations, especially in 
sensitivity and specificity. The direct or 
parasitological tests have unacceptably low 
sensitivity in the chronic phase. 
-There is a need for tools that can identify 
patients cured shortly after specific 
treatment. Other needs include a marker for 
prognosis and early diagnosis of congenital 
transmission. 
-Failure to detect parasites in infected 
newborns at one month of age due to low 
sensitivity of the assays.
Trypanosoma cruzi INP micromethod Parasite burden in some patients is 
below the detection limit
[102]
Serological methods Frequently display cross-reactivity 
against other pathogens and long term 
required for host seroreversion after 
the etiologic treatment of T. cruzi
infection. 
Sensitivity and specificity have low 
accuracy.
[103,104]
PCR Controversial for chronic phase
disease diagnosis. 
[105]
TOXOPLASMOSIS 
-Detection of oocysts is of little 
significance owing to short patency. 
The serological diagnosis of prenatal 
infection is difficult. 
-Low and focal distribution of parasites in 
the tissues or to the presence of non viable 
parasites. 
-Diagnosis of acute infection in human 
pregnancy is difficult since antibodies can 
be detected for a very long time after the 
acute phase.
Toxoplasma gondii Serological methods Equivocal results with conventional 
serological techniques are not 
uncommon when IgG titers are close 
to the cut-off value of the test 
[106]
SCHISTOSOMIASIS 
-Microscopic examination of excreta is the 
gold standard test albeit with some 
limitations like decrease of sensitivity in 
low-endemicity areas.
Schistosoma spp. Serology Antibody cross-reactivity with 
antigens from other helminths.
[107]
PCR Discrepancies among study findings 
regarding test sensitivity as a result of 
[108]
-Indirect methods using clinical, 
subclinical, or biochemical morbidity 
markers are not specific.
technical problems.
ECHINOCOCCOSIS 
-Considerable phenotypic variability 
between isolates of Echinococcus 
granulosus sensu lato
-Diagnosis is mostly based on imaging 
techniques but sometimes they are 
inconclusive.  
-The diagnostic sensitivity of the methods 
can strongly depend on the stage of 
infection. 
-Low specificity and sensitivity of the 
currently available commercial tools. 
-Prognosis-associated follow-up parameters 
are still lacking. Invasive procedures 
following therapeutic interventions in AE 
patients. 
-There is a need to develop reliable tools 
for improved viability assessment. 
-There is an urgent need for well-validated 
non-invasive markers. 
Echinococcus granulosus ELISA Sensitivity depends on the 
localization, size, number and stage 
of cysts. Several other factors could 
also affect the results of the tests. 
Cross-reactions with other parasites 
are common.  
Antibody persistence.
[109]
Imaging follow-up None of the available imaging 
procedures are currently able to 
accurately assess E. granulosus
viability and/or predict cyst 
progression/abortion
[110]
Echinococcus 
multilocularis 
Serology No single accurate assays for the 
follow-up: need for combining 
cytokine and chemokine levels with 
other circulating markers. 
Poor correlation between the presence 
of antibodies in animal serum and 
worms in the intestine
[110, 111]
Table 3. Microfluidic devices for the diagnosis of malaria infected cells. 
Usage Device/Platform Highlights References 
Characterization of 
disease states of single 
cells
Electric impedance microflow 
cytometry 
Allows differentiation of infected from uninfected 
RBCs as well as among different P. falciparum
intraerythrocytic asexual stages
[119] 
A polydimethylsiloxane 
microfluidic channel 
Potential tool for studying the invasion mechanism 
as well as performing antimalarial drug assays [120] 
Malaria diagnosis A cell microarray chip 
Offers higher sensitivity in the detection of malaria 
infected erythrocytes than conventional light 
microscopy 
[121] 
A lab-on-chip 
Capable of detecting all Plasmodium sp. with a DL 
for Plasmodium falciparum of 2 parasites/μL of 
blood 
[122] 
Polydimethylsiloxane microfluidic 
channels 
Indicate that surface morphologies can serve as an 
alternative biomarker for malaria diagnosis [123, 124] 
Separation of infected 
and non-infected cells 
Dielectrophoresis based continuous 
separation  
Higher inter-particle distance between red blood 
cells and plasmodium falciparum infected red blood 
cells 
[125] 
Detection of 
Plasmodium berghei in 
blood 
Acoustic fields to lyse cells DL of 30 parasites in a microliter-sized blood sample [126] 
Estimation of physical 
splenic filtration of 
infected cells 
A MCD filtration model Identify rheological diversity in RBC populations [127] 
Separation of infected 
cells based on their 
deformability 
A microfluidic device precisely 
controlling pressure 
Potential to study the pathophysiology and the 
effect of drugs [128] 
A hyperbolic converging 
microchannel for continuously 
monitoring cell deformation in the 
extensional flow region 
Overcomes the limitation of conventional methods 
by reducing experiment time [129] 
An automated microfabricated 
deformability cytometer 
Measure mechanical deformability and 
biomechanical properties of cells. Especially 
applicable to heterogeneous cell populations 
[130] 
A simple long straight channel 
microfluidic device 
An ideal technique for on-site iRBCs enrichment in 
resource-limited settings [131] 
A 2-microm microfluidic channel 
In contrast to P. falciparum-infected RBCs, mature 
P. vivax-infected RBCs readily became deformed 
through 2-microm constrictions
[132] 
Measurement of the 
density of single living 
cells
A microfluidic mass sensor Identifying Plasmodium falciparum malaria-infected erythrocytes [133] 
Imaging malaria 
parasites A lensfree on-chip microscope Imaging in thin blood smears [134] 
Monitoring heme 
dynamics and/or 
detecting hemozoin in 
malaria infected cells
A RALS approach Utility of the technique as a diagnostic and monitoring tool for minute sample volumes [135] 
A magneto-optical method Detect parasites at very low densities at the ring stage and in the case of the later stages [136] 
Table 4. List of some successfully applied sensors of parasites reported in the literature. 
Parasite  Bio-Sensing Approach Highlights Targets and/or Detection Limit References 
Leishmania sp. Immunosensor-based assay (monoclonal antibody coupled to a bioelectronic device) for detecting antigens quickly
Quantify amastigotes in organs for studies on 
pathogenesis and immunity Amastigotes [142] 
Plasmodium sp. Aptasensor device based on cationic polymers and gold nanoparticles 
Allows detection of the two main species of 
malaria (P. vivax and P. falciparum) Lactate dehydrogenase [143] 
Rolling-Circle-Enhance-Enzyme-Activity-Detection system 
(REAAD) 
Detection of malaria parasites in crude blood 
samples with a colorimetric detection system Topoisomerase I Activity [144] 
A label-free DNA biosensor based on quartz crystal 
microbalance (QCM) Specific for P. falciparum detection  Merozoite surface protein 2 [145] 
A miniaturized imaging system: sub-pixel resolving 
optofluidic microscope 
Combination of microfluidics and inexpensive 
image sensors an on-chip device RBCs infected with P. falciparum [146] 
A disposable plastic chip and a low-cost, portable, real-time 
PCR machine 
Containing a Peltier element for thermal cycling 
and a laser/camera setup for amplicon detection. DL of 2 parasites /μL
-1 of blood [122] 
A microfluidic device to measure red blood cell 
deformability (infected cells)
Combination of microfluidic and controlled 
pressures 
Deformability values of uninfected and 
parasitized cells [128] 
A droplet microfluidics platform DL of less than one parasite /μL
-1 in single drops 
of unprocessed blood or salive
Micrometer-sized products derived from 
the action of topoisomerase [137] 
Cryptosporidium 
parvum
A microbead immunoagglutination assay combined with Mie 
scatter detection in a microfluidic device
DL of ≤1 oocyst per large volume of water with 
the potential to be used in field situations
Cryptosporidium oocyst wall proteins 
(COWP) [147] 
A polydiacetylene(PDA) liposome chip based on 
fluorescence
Non-labeling detection of  the waterborne 
pathogen DL of 1 x 10
3 oocysts /mL-1 [148] 
A microfluidic device equipped with a micromesh and FITC-
labeled antibody.
Combination of micromesh for entrapment of 
oocysts with fluorescence immunoassay High-throughput counting of  oocysts [149] 
Schistosoma japonicum A piezoelectric immunosensor Mixed self-assembled monolayer membrane (mixed SAM) technology
S. japonicum antibody (SjAb) directly 
detected in the serum  [150] 
Glutaraldehyde or chitosan cross-linked electrochemical 
immunosensor High sensitivity and broad linear range response 
S. japonicum antigen (50 μg /L-1 Optimal 
concentration) [151] 
A liquid-phase piezoelectric immunosensor (LP-PEIS) Detect antigens in patients’ sera as well as ELISA but in a simple and quick operation S. japonicum circulating antigen (SjCAg) [152] 
Schistosoma 
haematobium 
On-chip imaging: mini-microscopes constructed from 
webcams and mobile phone cameras 
Low-cost diagnostics of urogenital 
schistosomiasis. Fields images of S. haematobium eggs [153] 
Giardia lamblia A PEMC biosensor immobilized with a monoclonal antibody The cysts bind to the antibody on the sensor changing the resonant frequency 
DL of 1-10 cysts/mL without a 
preconcentration step [154] 
Optofluidic microscopy imaging 
Successful microscopy imaging by 
flowing/scanning the target objects across a 
slanted hole array
Imaging of both Giardia trophozoites and 
cysts [155] 
Trypanosoma sp.  Gold electrode modified with a thiol sensitized with parasite proteins 100% specificity for the samples studied Human anti-T. cruzi IgG [156] 
Strongyloides stercoralis 
An immunological assay for diagnosing strongyloidiasis 
based on a novel diffraction-based optical bionsensor 
technology 
Serological assay based on real-time optical 
diffraction (NIE dot) 
Antigen called NIE derived from 
Strongyloides stercoralis L3-stage larvae [157] 
Entamoeba histolytica Portable screen-printed electrodes for the label-free electrochemical detection  Nano-yeast–scFv probes E. histolytica cyst antigens [158] 
Babesia bovis A device based on impedance spectroscopy combined with microfluidic Sorting based on microfabricated cell cytometer 
Allows single cell analysis of normal and 
B. bovis infected red blood cells [159] 
Lucilia cuprina
(Cutaneous myiasis) Electronic nose technology 
Array of sensors that react to volatile chemical 
compounds
Discriminate infection measuring parasite 
odour on the day of larval implantation [160] 
PEMC, piezoelectric-excited millimeter-sized cantilever; DL, Detection Limit 
